

# International Conference on Brain Disorders & Therapeutics

August 24-26, 2015 London, UK

## Interaction between *COMT* and *MTHFR* genetic variants protect against risk for bipolar II disorder in Han Chinese

Liang-Jen Wang<sup>1,2</sup>, Sheng-Yu Lee<sup>2,3</sup>, Yun-Hsuan Chang<sup>3</sup> and Ru-Band Lu<sup>3,4</sup>

<sup>1</sup>Chang Gung University, Taiwan

<sup>2</sup>Kaohsiung Medical University, Taiwan

<sup>3</sup>National Cheng Kung University, Taiwan

<sup>4</sup>Tainan Hospital, Taiwan

**Objectives:** Bipolar II disorder (BP-II), characterized by recurrent dysregulation of mood, is a serious and chronic psychiatric illness. However, BP-II is commonly under-recognized, even in psychiatric settings. Because dopaminergic disturbance is thought to be involved in the development of bipolar disorder (BPD), it seems essential to investigate dopamine-related genes like the catechol-O-methyltransferase (*COMT*) gene, which are involved in dopamine metabolism, and the methylenetetrahydrofolate reductase (*MTHFR*) gene, which may affect *COMT* methylation and *COMT* function. The current study examined the association and interaction of the *COMT* Val158Met and *MTHFR* C677T variants with BP-II.

**Methods:** Nine hundred seventy-eight participants were recruited: 531 with BP-II and 447 healthy controls. The genotypes of the *COMT* and *MTHFR* polymorphisms were determined using a polymerase chain reaction-restriction fragment length polymorphism analysis.

**Results:** After the *MTHFR* C677T genotypes in BP-II patients and Controls had been stratified, the *COMT* Val/Val variant was significantly more frequently detected in controls than in BP-II patients ( $P=0.008$ ). Logistic regression analysis showed a significant interaction effect of the *COMT* Val158Met Val/Val genotype and the *MTHFR* C677T C/T+T/T genotype ( $OR=0.57$ ,  $P=0.039$ ) for the protective effect on the odds of developing BP-II.

**Conclusion:** Our findings support preliminary evidence that the *COMT* and *MTHFR* genes interact in BP-II, and they imply the connection of both dopaminergic pathways and methylation pathways in the pathogenesis of BP-II.

[wangliangjen@gmail.com](mailto:wangliangjen@gmail.com)

## Notes: